Author

Sandra Muñoz-Galván

Consejo Superior de Investigaciones CientíficasORCID 0000-0003-0579-325XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:ATAC-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Ahmed A. AhmediD· 1 shared Amancio CarneroiD· 1 shared Aneesh Aggarwal· 1 shared Ashwag AlbukhariiD· 1 shared Ellina Mikhailova· 1 shared Eva M. Verdugo‐SivianesiD· 1 shared Hagan BayleyiD· 1 shared José M. Santos-PereiraiD· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ahmed A. AhmedORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyJournal of Experimental & Clinical Cancer ResearchPeer-reviewedFeb 25, 2024

Essential role of PLD2 in hypoxia-induced stemness and therapy resistance in ovarian tumors

Sandra Muñoz-Galván, Eva M. Verdugo‐Sivianes, José M. Santos-Pereira…·Amancio Carnero

This study identifies PLD2 as a mediator of hypoxia-induced stemness and chemoresistance in ovarian cancer, proposing PLD2 inhibition as a potential therapeutic strategy.

27 citationstop 4%

humanATAC-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJul 15, 2023

A 3D microtumour system that faithfully represents ovarian cancer minimal residual disease

Xingyun Yang, Mara Artibani, Yongcheng Jin…·Hagan Bayley

This paper develops a 3D microtumour system that mimics ovarian cancer minimal residual disease, showing it responds to chemotherapy and reflects molecular signatures of MRD.

DOI 10.1101/2023.07.15.549155

humanbulk RNA-seq

𝕏 PostBluesky